Improving bone and cardiovascular health

1

• Improving bone and cardiovascular health

Investor Presentation 1. Quarter 2008
2

• Exclusive strategic partnership agreement with
  Sumitomo Corp. to develop, market and sell the
  natural Vitamin K2
• Exclusive Research Science contract with VitaK
  (Maastricht University), the world leading
  research-company in vitamin K.
• RD is focused on developing K2 products in
  addition to build IPR to secure long-term market
  access
• Vitamin K2 is needed for optimal body utilization
  of Calcium and has documented beneficial effects
  on both Osteoporosis and Cardiovascular diseases

3

• NattoPharma focuses on Sales Product
  Development, through own Product IPR- based on
  clinical studies (GCP), leaving the production to
  Sumitomo.
• Product development may also be carried out in
  collaboration with End-clients, depending upon
  customer and market requirements.

End-client
Sumitomo Corp.
Production Process IPR
Product- Development Based on research
Product-design
End-product SM
Clinical Studies IPR
NattoPharma
4
Calcification in health and diseaseNattoPharma
focus
-

Lungs
Kidneys

• Scientific evidence
• Loss of calcification in bones
• Increased calcification heart,
• arteries and in joints
• Osteoporosis
• Cardiovascular disease
• Osteoarthrosis

Bone and cardiovascular health
Normal condition 99 of all Ca in bones
teeth 1 in circulation
Prevention Treatment
5
x
x
x
6
Market opportunities

• NattoPharma market strategy
• NattoPharma is working to include vitamin K2 in
  already existing global leading brands in the
  Dietary supplement (ex. Multivitamins, Calsium
  Omega3) Functional Food marked (Dairy-products).
  Thus, the revenue from the clients has the
  potential to go from zero to 3-diget million
  figure, only during the first year after signing
  with a large client.
• Dietary supplement
• Stand-alone / combination (Multivitamins,
  Calcium, Omega-3 and Vitamin D)
• Fortified food
• Fortified food with vitamins and minerals (Dairy
  segment, drinks)
• Pharmacy
• Strategy is to co-operate with a strategic partner

7
Market strategy

• Sell MenaQ7 as an ingredients into all ready
  existing global leading brands in the following
  market segments

Pharmacy
Volum vitamin K2
Fortified Food
Dietary supplement
2007 2008 2009 2010 2011
2012 2013
8
Headlines 1Q08

• RD
• Commenced clinical study combining MenaQ7 with
  Omega- and with Krill
• Longtime study approved and ready to start for
  postmenopausal 240 women to see MenaQ7s effect
  on bone structure and cardio vascular effects.

9
Headlines 1Q08

• MARKET
• Have signed distribution agreements in all
  European countries that we are able to MenaQ7
• Focus on Food segment both in USA. Official
  launch of MenaQ7 in Food at world larges Food
  Fair, Institute of Food Technology 2008 in New
  Orleans.
• Screening the market outside Europe and USA for
  potential distributors

10
Strategic Partnership Agremments

• LOI sign with Bayer ConsumerCare
• Bayer is no. 2 largest player in the global OTC
  market
• The Parties wants to negotiate about signing a
  global partnership agreement for MenaQ7.
• In search for a global partner also in the Food
  Market

11
Figures 1. quarter 2008

• Revenues NOK 5,1m (NOK 7,4m)
• EBIT NOK -5,9m (NOK -0,8m)
• Gross margin 55,1 (56,4)

12
Profit and Loss pr.31.03.2008
13
Balance pr. 31.03.2008
14
Balance pr. 31.03.2008
15
Cash flow statement Q1 - 2008
16
Outlook

• Expect EFSA approval during the summer
• Increase the investment in RD going forward
• Reiterate revenue expectation for 2008 of between
  NOK 80 90 mill in 2008
• Expect positive EBIT in 2008